Study of Side Effects of Patients Receiving Cisplatin in the Treatment of Cervical Cancer by Age Group

Main Article Content

Rachadapan Chaitosa
https://orcid.org/0000-0001-7014-3398
Worathida Maskasame

Abstract

Background: Cisplatin is one of the options of chemotherapy used to treat cervical cancer. Patient can experience side effects from drugs frequently with many factors as a catalyst including the age of the patient.


Objective: To compare the side effects of cervical cancer patients receiving concurrent chemoradiotherapy (Cisplatin) 2 rounds between patients ≤ 60 years and > 60 years.


Methods: A retrospective study, 70 cervical cancer patients undergoing concurrent chemoradiotherapy at Ramathibodi Hospital were investigated. Questionnaires about adverse effects were completed by patients at home 7 days after 1st and 2nd courses of combined therapy. The side effects of cervical cancer patients between groups was analyzed.


Results: Of 70 patients, there were 47 patients ≤ 60 years and 23 patients > 60 years. After the 1st course, life-threatening side effects occurred in 9 patient’s ≤ 60 years but none occurred in patients > 60 years. Younger patients also had significant more nausea than older patients (P < .05). After the 2nd course, younger patients also had significant more vomiting than older patients (P < .05). The most common side effects for both age groups were fatigue and anorexia respectively.


Conclusions: Patients younger than 60 year would experience significantly more symptoms of nausea and vomiting after the 1st and 2nd courses of concurrent chemoradiotherapy.


 

Article Details

How to Cite
Chaitosa, R., & Maskasame, W. (2020). Study of Side Effects of Patients Receiving Cisplatin in the Treatment of Cervical Cancer by Age Group. Ramathibodi Medical Journal, 43(4), 28–38. https://doi.org/10.33165/rmj.2020.43.4.200444
Section
Original Articles

References

Petsusiri J, Kakanaporn C. Basic Principles of Radiation Oncology in Gynecologic Cancer. In: Srisomboon J, Kietpeerakool C, eds. Gynecologic Oncology. Bangkok: The Royal Thai College of Obstetricians and Gynaecologists; 2011:355-375.

Division of Therapeutic Radiology and Oncology, Chula Cancer. Education and research: Radiotherapy for cervical carcinoma. https://www.chulacancer.net/education-inner.php?id=388. Accessed January 14, 2020.

Warwick GP. The Mechanism of action of alkylating agents. Cancer Res. 1963;23:1315-1333. https://cancerres.aacrjournals.org/content/23/8_Part_1/1315.full-text.pdf. Accessed January 14, 2020.

Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257-266. doi:10.2174/0929867033368484.

Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1-2):23-43. doi:10.1016/s0027-5107(01)00141-5.

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320. doi:10.1038/nrd1691.

Johnstone TC, Park GY, Lippard SJ. Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res. 2014;34(1):471-476.

Petrović M, Todorović D. Biochemical and molecular mechanisms of action of cisplatin in cancer cells. FU Med Bio. 2016;18(1):12-18.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378. doi:10.1016/j.ejphar.2014.07.025.

Division of Therapeutic Radiology and Oncology, Chula Cancer. Services: Knowledge of chemotherapy and the side effects of drugs. http://www.chulacancer.net/services-list-page.php?id=352#5. Accessed January 14, 2020.

Sookpresert A. A step by step practical guide before giving chemotherapy. Presented as part of Workshop and Traineeship for Oncology Pharmacy Practitioners; 2011:40-56. http://thaihp.org/index2.php?option=showfile&tbl=home&id=972. Accessed January 14, 2020.

Department of Older Persons, Ministry of Social Development and Human Security. The Act on the Elderly, B.E. 2546 (2003 A.D.). Bangkok: Ministry of Social Development and Human Security; 2010. http://www.dop.go.th/download/laws/regulation_th_20160807155130_1.pdf. Accessed January 14, 2020.

Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89(9):1953-1960. doi:10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y.

Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94(3):173-181. doi:10.1093/jnci/94.3.173.

US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Published November 27, 2017. Accessed January 14, 2020.

Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer. 2008;16(2):201-208. doi:10.1007/s00520-007-0343-7.

Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer. 2011;19(10):1549-1563. doi:10.1007/s00520-010-0982-y.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-1346. doi:10.1016/0360-3016(95)00060-C.

Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006;14(9):890-900. doi:10.1007/s00520-006-0040-y.